financetom
Business
financetom
/
Business
/
Semiconductor testing firm FormFactor beats Q3 revenue estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Semiconductor testing firm FormFactor beats Q3 revenue estimates
Oct 29, 2025 1:46 PM

Overview

* FormFactor ( FORM ) reports Q3 revenue of $202.7 mln, beating analysts' expectations

* Adjusted net income for Q3 beats estimates, reaching $25.7 mln

* Company's gross margin improved to 39.8% from 37.3% in Q2

Outlook

* FormFactor ( FORM ) expects Q4 revenue of $210 mln +/- $5 mln

* Company anticipates Q4 gross margin of 40% +/- 1.5%

* FormFactor ( FORM ) projects Q4 non-GAAP EPS of $0.35 +/- $0.04

Result Drivers

* DRAM PROBE CARDS - Double-digit sequential growth in DRAM probe cards, driven by HBM technology

* SYSTEMS SEGMENT - Anticipated revenue increase in Systems Segment, with growth expected to continue in Q4

* GROSS MARGIN IMPROVEMENT - Rapid gross margin improvement actions led to a 250 basis point increase from Q2

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $202.70 $200 mln

Revenue mln (9

Analysts

)

Q3 Beat $25.68 $19.30

Adjusted mln mln (7

Net Analysts

Income )

Q3 Net $15.66

Income mln

Q3 Gross 39.80%

Margin

Q3 41%

Adjusted

Gross

Margin

Q3 Free $19.66

Cash mln

Flow

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the semiconductor equipment & testing peer group is "buy."

* Wall Street's median 12-month price target for FormFactor Inc ( FORM ) is $35.00, about 21.2% below its October 28 closing price of $42.42

* The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blackstone, Lunate Form Partnership to Create Platform Targeting $5 Billion of Gulf Cooperation Council Warehouses
Blackstone, Lunate Form Partnership to Create Platform Targeting $5 Billion of Gulf Cooperation Council Warehouses
Oct 6, 2025
07:46 AM EDT, 10/06/2025 (MT Newswires) -- Blackstone (BX) and Lunate said Monday they have formed a partnership to establish a platform that will invest $5 billion in warehouse assets across the Gulf Cooperation Council region. The Gulf Logistics Infrastructure Development Enterprise platform will focus mainly on greenfield developments, complemented by selective portfolio acquisitions and sale-leaseback deals. The companies said...
Collective Mining Announcing Agnico Eagle's Intention To Exercise Its Participation Rights In Offering
Collective Mining Announcing Agnico Eagle's Intention To Exercise Its Participation Rights In Offering
Oct 6, 2025
07:48 AM EDT, 10/06/2025 (MT Newswires) -- Collective Mining Ltd. ( CNL ) said Monday that, further to announcing last week a C$125 million 'bought deal' public offering of common shares led by a syndicate of underwriters, Agnico Eagle Mines Limited ( AEM ) has indicated to CNL that it intends to exercise its participation right to subscribe for 789,473...
Skye Bioscience Phase 2 Trial of Weight Loss Drug Nimacimab Misses Primary Endpoint; Shares Plunge Pre-Bell
Skye Bioscience Phase 2 Trial of Weight Loss Drug Nimacimab Misses Primary Endpoint; Shares Plunge Pre-Bell
Oct 6, 2025
07:47 AM EDT, 10/06/2025 (MT Newswires) -- Skye Bioscience ( SKYE ) shares plummeted more than 58% in recent premarket activity after it said Monday that its phase 2a trial of nimacimab to treat patients with obesity missed its primary endpoint of weight loss compared with placebo. The company said its preliminary analysis found that the 200 mg, subcutaneous weekly...
Paris prosecutor's office probing Siri, Apple's voice assistant
Paris prosecutor's office probing Siri, Apple's voice assistant
Oct 6, 2025
PARIS (Reuters) -The Paris prosecutor's office said on Monday it was investigating Siri, Apple's ( AAPL ) voice assistant, after it received a complaint. Politico reported earlier on Monday that Apple ( AAPL ) is suspected of using users' recordings without their knowledge. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved